A Multicenter, Randomized, Phase 2 Study to Assess the Feasibility, Safety and Efficacy of OTO-104 Given by Intratympanic Administration in Subjects at Risk for Ototoxicity From Cisplatin Chemotherapy Regimens in the Treatment of Cancer
Phase of Trial: Phase II
Latest Information Update: 21 Apr 2017
At a glance
- Drugs Dexamethasone (Primary)
- Indications Hearing loss
- Focus Therapeutic Use
- Sponsors Otonomy
- 16 Dec 2016 Status changed from planning to recruiting.
- 03 Nov 2016 According to an Otonomy media release, this trial is expected to initiate in the fourth quarter of 2016.
- 09 May 2016 This trial is expected to be initiated in the second half of 2016, according to an Otonomy media release.